Back to Authors

Vavricka, S

Mayo Clinic

University Hospital Zurich

Citations 3

The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy
Hedin, Charlotte , Vavricka, S, Stagg, Andrew J. , Schoepfer, Alain , Raine, Tim , Navarini, Alexander A. , Jong, Andrea E. van der Meulen‐de , Maul, Jochen , Katsanos, K., Kagramanova, A , Greuter, Thomas , González‐Lama, Yago , Ellul, Pierre , Burisch, Johan , Becker, Markus , Bamias, Giorgos , Rieder, Florian , Navarini, Alexander , Puig, L. , Pleyer, Uwe , Gaalen, Floris A van , Bettenworth, Dominik , Raine, Tim

Journal of Crohn's and Colitis | November 13, 2018 | Volume: 13 | Issue: 5 | Pages: 541-554

10.1093/ecco-jcc/jjy191 Get It

Swallowed topical corticosteroids reduce the risk for long‐lasting bolus impactions in eosinophilic esophagitis
Kuchen, Tanja, Straumann, Alex , Safroneeva, Ekaterina , Romero, Yvonne , Bussmann, Christian, Vavricka, S, Netzer, Peter, Reinhard, Antoine , Portmann, Susanne, Schoepfer, Alain

Allergy | June 3, 2014 | Volume: 69 | Issue: 9 | Pages: 1248-1254

10.1111/all.12455 Get It

Abstract Background Long‐lasting food impactions requiring endoscopic bolus removal occur frequently in patients with eosinophilic esophagitis ( E o E ) and harbor a risk for severe esophageal injuries. We evaluated whether treatment with swallowed topical corticosteroids is able to reduce the risk of occurrence of this complication. Methods We analyzed data from the S wiss E o E C ohort Study. Patients with yearly clinic visits, during which standardized assessment of symptoms, endoscopic, histologic, and laboratory findings was carried out, were included. Results A total of 206 patients (157 males) were analyzed. The median follow‐up time was 5 years with a total of 703 visits (mean 3.41 visits/patient). During the follow‐up period, 33 patients (16 % of the cohort) experienced 42 impactions requiring endoscopic bolus removal. We evaluated the following factors regarding the outcome ‘bolus impaction’ by univariate logistic regression modeling: swallowed topical corticosteroid therapy ( OR 0.503, 95%‐ CI 0.255–0.993, P = 0.048), presence of EoE symptoms ( OR 1.150, 95%‐ CI 0.4668–2.835, P = 0.761), esophageal stricture ( OR 2.832, 95%‐ CI 1.508–5.321, P = 0.001), peak eosinophil count >10 eosinophils/ HPF ( OR 0.724, 95%‐ CI 0.324–1.621, P = 0.433), blood eosinophilia ( OR 1.532, 95%‐ CI 0.569–4.118, P = 0.398), and esophageal dilation ( OR 1.852, 95%‐ CI 1.034–3.755, P = 0.017). In the multivariate model, the following factors were significantly associated with bolus impaction: swallowed topical corticosteroid therapy ( OR 0.411, 95%‐ CI 0.203–0.835, P = 0.014) and esophageal stricture ( OR 2.666, 95%‐ CI 1.259–5.645, P = 0.01). Increasing frequency of use of swallowed topical steroids was associated with a lower risk for bolus impactions. Conclusions Treatment of E o E with swallowed topical corticosteroids significantly reduces the risk for long‐lasting bolus impactions.